The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement.
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Eisai; Exelixis; Helio Health; Incyte; Ipsen; Merck Serono; Merus NV (I); Neogene Therapeutics (I); Newbridge Pharmaceuticals; Novartis (I); QED Therapeutics; Roche/Genentech; SERVIER; Tempus (I); Thetis Pharma (I); Vector Health; Yiviva
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
 
Ivan Borbath
Honoraria - AstraZeneca (Inst); Ipsen (Inst); Roche (Inst); SERVIER (Inst); Taiho Pharmaceutical (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Ipsen (Inst); Roche (Inst); SERVIER (Inst)
Research Funding - SERVIER
Travel, Accommodations, Expenses - Roche (Inst)
 
Sameek Roychowdhury
Stock and Other Ownership Interests - Johnson & Johnson (I)
Honoraria - Illumina; Integrated DNA Technologies
Consulting or Advisory Role - AbbVie; Incyte; Incyte; Merck; QED Therapeutics; Seagen
Research Funding - Ignyta; Incyte; QED Therapeutics; Takeda
 
Lipika Goyal
Consulting or Advisory Role - Alentis Therapeutics; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Compass Therapeutics; Eisai/H3 Biomedicine; Exelixis; Genentech; Incyte; Kinnate Biopharma; Merck; QED Therapeutics; SERVIER; Sirtex Medical; Synthekine; Taiho Pharmaceutical; TransThera Biosciences; Tyra Biosciences
(OPTIONAL) Uncompensated Relationships - Agios; Boehringer Ingelheim; Boehringer Ingelheim; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Angela Lamarca
Consulting or Advisory Role - Albireo Pharma; AstraZeneca/MedImmune; Boehringer Ingelheim; Boston Scientific; EISAI; GENFIT; Ipsen; MSD Oncology; Nutricia; QED Therapeutics; Roche; SERVIER; Taiho Pharmaceutical; TransThera Biosciences
Speakers' Bureau - Advanced Accelerator Applications; Advanz Pharma; AstraZeneca/MedImmune; Eisai; Incyte; Ipsen; Merck; MSD Oncology; Novartis; Pfizer; QED Therapeutics; Roche; SERVIER
Research Funding - Albireo Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); GENFIT (Inst); Ipsen; Merck (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Abbott Nutrition; Advanced Accelerator Applications; Advanz Pharma; Bayer; Celgene; Delcath Systems; Ipsen; Mylan; Novartis; Pfizer; Roche; Sirtex Medical
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Rachna T. Shroff
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Exelixis; Genentech; Incyte; Jazz Pharmaceuticals; Merck; Merus; Taiho Pharmaceutical
Research Funding - Actuate Therapeutics; Bayer; Bristol-Myers Squibb; Exelixis; Faeth Therapeutics; Immunovaccine; Loxo/Lilly; Merck; NGM Biopharmaceuticals; Novocure; Nucana; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Catalin Tamas
Employment - Helsinn Healthcare
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Helsinn Healthcare
 
David M Savastano
Employment - Helsinn Therapeutics (US) Inc.
Stock and Other Ownership Interests - GlaxoSmithKline; Pfizer; Viatris
 
David Friedrich Van Veenhuyzen
Employment - Navire; QED Therapeutics
Stock and Other Ownership Interests - BridgeBio Pharma
Consulting or Advisory Role - Navire
 
Cindy Xu
Employment - QED Therapeutics
Stock and Other Ownership Interests - QED Therapeutics
Consulting or Advisory Role - QED Therapeutics
 
Jacki Solanas
Employment - QED Therapeutics
Stock and Other Ownership Interests - QED Therapeutics
 
Elizabeth Freas
Employment - QED Therapeutics
Stock and Other Ownership Interests - QED Therapeutics
Consulting or Advisory Role - QED Therapeutics